Media headlines about The Joint Corp. (NASDAQ:JYNT) have trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. The Joint Corp. earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0034422693485 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of equities research analysts have recently weighed in on JYNT shares. ValuEngine upgraded The Joint Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, June 6th. Craig Hallum started coverage on The Joint Corp. in a research report on Wednesday, June 14th. They issued a “buy” rating and a $5.75 price objective on the stock. Roth Capital started coverage on The Joint Corp. in a research report on Thursday, July 27th. They issued a “buy” rating and a $5.70 price objective on the stock. Finally, Maxim Group reiterated a “buy” rating and issued a $7.00 price objective on shares of The Joint Corp. in a research report on Friday, August 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The Joint Corp. currently has a consensus rating of “Buy” and a consensus target price of $5.61.
Shares of The Joint Corp. (NASDAQ:JYNT) traded up 0.68% during midday trading on Monday, hitting $4.42. The stock had a trading volume of 9,146 shares. The company’s 50 day moving average is $4.17 and its 200 day moving average is $3.93. The Joint Corp. has a 52-week low of $1.96 and a 52-week high of $5.07. The company’s market cap is $58.25 million.
The Joint Corp. (NASDAQ:JYNT) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The Joint Corp. had a negative return on equity of 103.25% and a negative net margin of 48.08%. The firm had revenue of $6.02 million for the quarter, compared to the consensus estimate of $5.76 million. On average, analysts anticipate that The Joint Corp. will post ($0.33) earnings per share for the current year.
In other The Joint Corp. news, Director James H. Amos, Jr. purchased 10,000 shares of The Joint Corp. stock in a transaction dated Friday, June 30th. The shares were purchased at an average cost of $3.85 per share, for a total transaction of $38,500.00. Following the completion of the acquisition, the director now owns 57,295 shares in the company, valued at approximately $220,585.75. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO John P. Meloun purchased 6,850 shares of The Joint Corp. stock in a transaction dated Tuesday, June 27th. The stock was acquired at an average price of $3.69 per share, for a total transaction of $25,276.50. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 20,670 shares of company stock worth $78,140. Company insiders own 6.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/25/the-joint-corp-jynt-receives-daily-news-sentiment-score-of-0-17.html.
About The Joint Corp.
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.
Receive News & Ratings for The Joint Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Joint Corp. and related companies with MarketBeat.com's FREE daily email newsletter.